Skip to main content
. 2022 Aug 18;10(8):e004904. doi: 10.1136/jitc-2022-004904

Figure 2.

Figure 2

Real-world duration of response (DOR) and real-world progression-free survival (PFS) among all avelumab-treated patients, by stage of avelumab initiation and by line of avelumab treatment. KM, Kaplan-Meier; NR, not reached; 1L, first line; 2L+, second or later line.